Category Archives: IPR

USPTO decision finding Sony’s CD recording claims obvious reversed by Federal Circuit due to improper means-plus-function determination (“computer-implemented” limitation requires algorithm)

Sony Corporation v. Andrei Iancu (USPTO as intervenor) Docket No. 2018-1172 (IPR2016-00834) PROST, NEWMAN (D), DYK May 22, 2019 Brief summary: IPR FWD obviousness finding reversed and remanded as disputed means-plus-function limitation is computer-implemented and requires an algorithm and Board … Continue reading

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Means-plus-function | Leave a comment

Fed. Cir. affirms PTAB IPR decision finding BTGs’s ZYTIGA® (abiratone) Orange Book ‘438 method of treatment patent invalid for obviousness

BTG Int. Ltd. and Janssen Biotech, Inc. et al. v. Amneal Pharmaceuticals LLC, et al. Docket Nos. 2019-1147, -1148. -1323, -1324, -1325 MOORE, WALLACH, CHEN May 14, 2019 Brief summary: PTAB IPR decision finding BTGs’s ZYTIGA® (abiratone) Orange Book ‘438 … Continue reading

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

Grünenthal GmbH v. Antecip Bioventures II LLC

PGR2018-00001 (US 9,539,268 B2) Final Written Decision April 29, 2019 Brief summary: GG found to have demonstrated by a preponderance of the evidence that Antecip’s claims related to zoledronic acid and methods for using the same to treat arthritis are … Continue reading

Posted in Enablement, Inter Parties Review (IPR), IPR | Leave a comment

Neptune Genetics, LLC et al. v. Eli Lilly & Company

Docket No. 2018-1257-8, -1288, -1290 (multiple IPRs) Moore, WALLACH, HUGHES April 26, 2019 Brief summary: Board IPR decisions finding Lilly’s claims relating to administration of vitamin B12 with pemetrexed were not shown to be obvious affirmed. Summary: Neptune Genetics (NG) … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

ATI Technologies ULC v. Andrei Iancu (USPTO)

Docket No. 2016-2222, -2406, -2608 (IPR2015-00325, -00326, -00330) NEWMAN, O’MALLEY, WALLACH April 11, 2019 Brief summary: PTAB finding of invalidity due to ATI’s lack of diligence before filing its patent applications reversed (e.g., “[t]he PTAB identified no delays” or “gaps … Continue reading

Posted in Conception and Reduction to Practice, Diligence, Inter Parties Review (IPR), IPR | Leave a comment

Incyte Corp. v. Concert Pharm. Inc.

IPR2017-01256 (U.S. Pat. No. 9,249,149 B2) PTAB Final Written Decision April 8, 2019 Brief summary: PTAB IPR decision found Concert’s ‘149 patent claims to a deuterated ruxolitinib relating to its CTP-543 product in development invalid for obviousness. Summary: Concert’s ‘149 … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

Merck Sharpe & Dohme Corp. v. Pfizer Inc.

IPR2017-02131 U.S. Pat. No. 9,492,559 B2 March 13, 2019 Brief summary: Board FWD found that the challenged claims relating to Pfizer’s Prevnar(TM) 13 vaccine were shown by a preponderance of the evidence to be unpatentable for obviousness. Summary: The Board … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away | Leave a comment